Scientists in Amsterdam Just Destroyed Breast Cancer Tumors in 11 Days WITHOUT Chemotherapy

A study conducted and initialized by a Professor at European Breast Cancer Conference in Amsterdam know as Professor Nigel Bundred, explained how they tested the efficacy of a pair of drugs Herceptin also known as trastuzumab and the other one is Lapatinib.

Scientists in Amsterdam Just Destroyed Breast Cancer Tumors in 11 Days WITHOUT Chemotherapy

These two drugs have been attested in the treatment of breast cancer previously, but in just a latter days of studies, this is the first time the combination of the two drugs have been undertaken and used before surgeries, operations, and chemotherapy.

What they had discovered is the data regarding the elimination of some types of breast cancer in just a given time and days.

Supported and funded by the Foundation of Cancer Research UK. The foundation aimed to utilize these drugs to fight back against a protein called HER2 or Human Epidermal Growth Factor Receptor 2.

Typically affects the division of cancer cells and help in the growth of the disease. This cancer type is likely unstoppable returning unlike other types of cancer.

In addition to what this treatment makes more appealing to the public, the fact that it excludes the necessity for chemotherapy and surgical operations.
The temporary side effects like vomiting, hair loss, and fatigue are included. This made the treatment less effective. Chemotherapy is not totally effective, nor it is an option for a certain patient if he would rather choose this treatment or not, so any alternatives are welcomed.

Results of the Study

258 women with HER2 positive breast cancer were selected for the study, with half being put on the drug combo and the other half were the control group.

What they found was that of those on the drug, 12% had no cancer cells remaining within two weeks, and 18% of cases featured dramatically shrunken tumors.

Compared to the control group who were only given Herceptin, they were found to have 0% with no trace of cancer cells, and only 4% showed a drop in tumor size.

The two drugs combined have a major effect on breast cancer cells as opposed to being used on their own.

The current problem they are facing is that Herceptin's licensing and approval makes it only available for utilization alongside with the chemotherapy alone. However, the results of this study will possibly help to change that perspective.

The problem currently, however, is that Herceptin’s licensing makes it only available for use alongside chemotherapy and not alone. The results of this study may help to change that though.